TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06768775

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pastured Livestock Diet
Description: Participants will consume a diet consisting of animal-source foods (chicken, beef, pork, and eggs) from regenerative/pastured farming practices. Foods will be provided weekly in specific quantities for a 16-week intervention. Adherence will be monitored through dietary logs and ASA24 dietary assessments.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional Livestock Diet
Description: Participants will consume a diet consisting of animal-source foods (chicken, ground, pork, and eggs) from conventional farming practices. Foods will be provided weekly in specific quantities for a 16-week intervention. Adherence will be monitored through dietary logs and ASA24 dietary assessments.
Study: NCT06768216

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indianized version of Mediterranean Diet
Description: Indo Mediterranean diet will have Carbohydrates 40-45%, fats 30-35% and proteins 15-20%. Mediterranean diet, it will be specified to use Mustard oil, use of specific fruits like orange, apple, mosambi (avoid high glycemic fruits), use more of green leafy vegetables, Use of multigrain atta (Home made- 10 kg of multigrain atta will have - 8 kg of wheat + 500g each of Ragi+Bajra+ Jowar + Chana dal flour).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat Diet
Description: Low fat diet will have 50-60% carbohydrate, 20-30% fat (with \<10% saturated fat), and 20% protein. In the Low Fat Diet group, there will be only be restriction of total fat content to less than \<30%. They can use whichever household oil, consume any fruit or vegetables, any atta and no restriction on diary or non-vegetarian diet. Along with this, both groups will be given a list of do's and dont's. In the list of Do's , it will be mentioned to Eat plenty of vegetables, Fruits, Nuts, Whole grains, Screen time of less \<2 hrs /day (According to American academy of pediatrics) and Average hours of sleep in a day for age 8-18 = 8-9 hrs (According to American academy of sleep medicine). In the dont's list, it will be mentioned to avoid Sugar, Soda, Beverages, cold drinks, processed juices, processed food, junk foods, Maida, Ice cream, Creamy Desserts, Biscuit, chips and cake.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: At least 45- 60 mins of exercise (peer group activity - cycling, football, brisk walking),

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: At least 45- 60 mins of exercise (peer group activity - cycling, football, brisk walking),
Study: NCT06769438

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS
Description: ERAS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS
Description: ERAS
Study: NCT05277636

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Mannitol)
Study: NCT04836026

Intervention type: DEVICE
Intervention: HF20™
Description: HF20™ will be used for CRRT
Study: NCT06084819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
Description: 1. Azacytidine (75mg/m2/day, days 1 to 7).~2. Cytarabine (75-100mg/m2 q12h, days 1 to 5).~3. Aclacinomycin(20mg/day, days 1,3,5).~4. Chidamide(30mg/day , days 1,4,8,11).~5. Venetoclax (100mg on day 1,200mg on day 2,400mg on days 3-14).~6. Granulocyte colony stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best-Available Therapy(BAT) Regimen
Description: 1. FLAG regimen:Fludarabine(30mg/m2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~2. CLAG regimen:Cladribine(5mg/2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~3. MAE regimen:Mitox(10mg/m2,days 1 to 5)+VP-16(100mg/m2,days 1 to 5)+Cytarabine (100-150mg/m2,days 1 to 7)~4. DCAG regimen:Decitabine(20mg/m2,days 1 to 5)+Aclacinomycin(20mg/day on days 1,3,5)+Cytarabine (100mg q12h,days 1 to 5)+Granulocyte colony-stimulating factor(300 ug/day,day 0 until agranulocytosi recovery)~5. HAA regimen:HHT(2mg/m2,days 1 to 7)+Aclacinomycin(20mg/day,days 1 to 7) and Cytarabine (100-200 mg/m2, days 1 to 5);~6. HAD regimen:HHT(2mg/m2,days 1 to 7)+Daunorubicin(45mg/m2/day,days 1 to 3)+Cytarabine (100-200 mg/m2,days 1 to 5).
Study: NCT05887843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone + Azelastine
Description: Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray, two actuations administered in each nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone + Azelastine
Description: Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray, two actuations administered in each nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone + Azelastine
Description: Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray, two actuations administered in each nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate
Description: Mometasone Furoate 50 μg (per actuation) nasal spray, two actuations administered in each nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate
Description: Mometasone Furoate 50 μg (per actuation) nasal spray, two actuations administered in each nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate
Description: Mometasone Furoate 50 μg (per actuation) nasal spray, two actuations administered in each nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine Hydrochloride
Description: Azelastine Hydrochloride 140 μg (per actuation) nasal spray, two actuations administered in each nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine Hydrochloride
Description: Azelastine Hydrochloride 140 μg (per actuation) nasal spray, two actuations administered in each nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine Hydrochloride
Description: Azelastine Hydrochloride 140 μg (per actuation) nasal spray, two actuations administered in each nostril
Study: NCT06339411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin post-mechanical thrombectomy, initiated within 24 hours of stroke onset and continued for 14 days. The study assessed neurological, neuropsychological, and biomarker outcomes at multiple time points post-stroke to evaluate the effects of Cerebrolysin on recovery.
Study: NCT04735692

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full mouth or quadrant SRP
Description: Full mouth or quadrant SRP

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Full mouth or quadrant SRP
Description: Full mouth or quadrant SRP
Study: NCT04015921

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention. Participants will be asked to complete a questionnaire and computer-based tasks.

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention. Participants will be asked to complete a questionnaire and computer-based tasks.
Study: NCT05299931

Intervention type: DRUG
Group type: OTHER
Intervention: Ustekinumab
Description: dose escalation from every 8 weeks to every 4 weeks only in arm 2

Intervention type: DRUG
Group type: OTHER
Intervention: Ustekinumab
Description: dose escalation from every 8 weeks to every 4 weeks only in arm 2
Study: NCT04532190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS)
Study: NCT06445842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The protocol involves a 10-minute warm-up and cool-down session, followed by two sets of high-intensity circuit training exercises (bench press, squats, overhead press, calf raising, barbell row, deadlifts) that last 12 minutes each (6 stations×2sets). There will be a 3-minute break between the exercise sets. The heart rate required during the exercise will be between 70-90% of their maximum capacity and a pre-scale rate of 7.5. The intensity of the exercise will be progressive each two weeks, commencing at 50% of their one rep max and increasing to 80% in their last week. During the initial phase, participants will be required to complete eight reps for each exercise. We will encourage them to increase their intensity level every two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: This group will need to maintain their sedentary lifestyle without changing their activity levels or diet
Study: NCT04818645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASSERT Insertable Cardiac Monitor
Description: Subjects will be subcutaneously implanted with an Abbott ASSERT ICM with the device implant procedure per standard of care and current labelling. Data related to subjects' arrhythmias, via the Merlin.net Patient CareNetwork will be transmitted on a monthly basis to the treating physician and subsequently to the study coordination and database center (CCRC) at the University of Rochester. Data on the frequency/types of symptomatic (patient triggered) versus ICM detected (asymptomatic) arrhythmic events will be collected and adjudicated. Clinical data on medication, device interventions, cardiovascular events will be collected at follow-up visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Management and monitoring
Description: Subjects randomized to the conventional management arm of the trial will undergo arrhythmia monitoring based on clinical indications and per standard available modalities including periodic electrocardiograms (ECG), Holter and/or event monitoring.
Study: NCT06769438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS
Description: ERAS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROFIM
Description: teleexpertise solution connecting extra-hospital and intra-hospital practitioners

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DEEPSEN
Description: virtual reality headset to reduce anxiety

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RDS
Description: patch to continuously monitor patients' physiological parameters at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Get ready
Description: digital solution for managing patients at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumiradx
Description: taking CRP at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Surgery
Description: recording of the different operating times
Study: NCT06769646

Intervention type: OTHER
Intervention: No tretament given
Description: No treatment given
Study: NCT06767800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection+Benmelstobart
Description: TQB2102 for injection is an antibody-coupled drug Benmelstobart is a Programmed cell death -Ligand 1 (PD-L1) Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection+Benmelstobart+Capecitabine
Description: TQB2102 for injection is an antibody-coupled drug Benmelstobart is a PD-L1 Antibody Capecitabine is a fluoropyrimidine
Study: NCT06769256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTNK-tPA, 4-8 mg
Description: Intracoronary influsion of rhTNK-tPA (4 mg). After 10 minutes of administration, 4 mg may be given again if the thrombus burden is not significantly reduced.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Description: Intracoronary influsion of Tirofiban (10 µg/kg) , and then administered intravenously at 0.075-0.15 µg/kg.min for 36 h or longer
Study: NCT06076304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet
Description: Amoxicillin/clavulanate, oral, 875mg/125mg twice daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet
Description: Amoxicillin/clavulanate, oral, 875mg/125mg twice daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for amoxicillin/clavulanate, oral, twice daily for 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo for amoxicillin/clavulanate, oral, twice daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide nasal spray
Description: Budesonide nasal spray, 32 mcg per spray, 2 sprays per nostril, once per day

Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide nasal spray
Description: Budesonide nasal spray, 32 mcg per spray, 2 sprays per nostril, once per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C-reactive protein
Description: Measurement of C-reactive protein level in capillary blood

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C-reactive protein
Description: Measurement of C-reactive protein level in capillary blood

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: C-reactive protein
Description: Measurement of C-reactive protein level in capillary blood

Intervention type: OTHER
Group type: OTHER
Intervention: C-reactive protein
Description: Measurement of C-reactive protein level in capillary blood
Study: NCT06318442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Oral Product
Description: Oral semaglutide 3mg once uptitrated to twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Oral Tablet
Description: Metformin modified release tablets 500mg once daily uptitrated to twice daily).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT05301270

Intervention type: DIAGNOSTIC_TEST
Intervention: EMG Evaluation
Description: Muscle activations in the lower extremity and trunk muscles during compensatory postural responses will be evaluated. The Delsys Trigno IM (Delsys Inc. Natick, Massachusetts, USA) wireless surface electromyography (EMG) system will be used to evaluate muscle activation. In the lower extremity; Muscle activations of tibialis anterior, gastrocnemius, quadriceps and hamstring muscle groups and erector spinae in the trunk will be evaluated. While the muscle groups above the stump on the amputated side of the individuals in the amputation group will be evaluated, all muscle groups specified on the healthy side will be evaluated. In the control group, all muscle groups on the dominant side, but on the non-dominant side, all other muscles except the tibialis anterior and gastrocnemius muscles will be evaluated in order to be compatible with the amputation group.

Intervention type: DIAGNOSTIC_TEST
Intervention: EMG Evaluation
Description: Muscle activations in the lower extremity and trunk muscles during compensatory postural responses will be evaluated. The Delsys Trigno IM (Delsys Inc. Natick, Massachusetts, USA) wireless surface electromyography (EMG) system will be used to evaluate muscle activation. In the lower extremity; Muscle activations of tibialis anterior, gastrocnemius, quadriceps and hamstring muscle groups and erector spinae in the trunk will be evaluated. While the muscle groups above the stump on the amputated side of the individuals in the amputation group will be evaluated, all muscle groups specified on the healthy side will be evaluated. In the control group, all muscle groups on the dominant side, but on the non-dominant side, all other muscles except the tibialis anterior and gastrocnemius muscles will be evaluated in order to be compatible with the amputation group.

Intervention type: DIAGNOSTIC_TEST
Intervention: EMG Evaluation
Description: Muscle activations in the lower extremity and trunk muscles during compensatory postural responses will be evaluated. The Delsys Trigno IM (Delsys Inc. Natick, Massachusetts, USA) wireless surface electromyography (EMG) system will be used to evaluate muscle activation. In the lower extremity; Muscle activations of tibialis anterior, gastrocnemius, quadriceps and hamstring muscle groups and erector spinae in the trunk will be evaluated. While the muscle groups above the stump on the amputated side of the individuals in the amputation group will be evaluated, all muscle groups specified on the healthy side will be evaluated. In the control group, all muscle groups on the dominant side, but on the non-dominant side, all other muscles except the tibialis anterior and gastrocnemius muscles will be evaluated in order to be compatible with the amputation group.
Study: NCT05583214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: 8mg of Ondansetron IV stat will be given to the group after induction of spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8mg
Description: 8mg of Dexamethasone IV stat will be given to the group after induction of spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be given IV stat to the group after induction of spinal anesthesia
Study: NCT04933201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Perioperative musical intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine perioperative treatment
Description: Routine perioperative treatment
Study: NCT06397274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stemchymal
Description: Patients will receive Stemchymal® through intravenous infusion
Study: NCT06216808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyperQure Renal Denervation System
Description: The HyperQure RDN System consists of a generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a laparoscopic approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessel is planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN is also performed on the branch or accessory vessel confirmed to be suitable for the procedure by CTA.
Study: NCT06397274

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive Placebo through intravenous infusion
Study: NCT06439823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiMyo®/Syde®
Description: Subjects will be equipped with magneto-inertial sensors (ActiMyo®/Syde®) and passive reflective markers belonging to the MoCap® motion capture system.
Study: NCT06104514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
Study: NCT05011123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (produced on serum-free Vero cells)
Description: Powder and diluent for suspension for injection - Subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine
Description: Powder and diluent for suspension for injection - Subcutaneous
Study: NCT05465512

Intervention type: OTHER
Intervention: response to neoadjuvant chemotherapy
Description: Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).

Intervention type: OTHER
Intervention: response to neoadjuvant chemotherapy
Description: Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
Study: NCT06190262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The intervention is community based group psychoeducation
Description: The intervention is community based group psychoeducation
Study: NCT06320925

Intervention type: DEVICE
Intervention: Standard of Care Treatment
Description: Subject has undergone joint space repair using one of the study devices and meets eligibility criteria
Study: NCT04916119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI323
Description: In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K
Study: NCT05050578

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Commercially available, silicone hydrogel, spherical contact lenses used as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Commercially available, silicone hydrogel, spherical contact lenses used as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Commercially available, silicone hydrogel, spherical contact lenses used as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Commercially available, silicone hydrogel, spherical contact lenses used as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based contact lens cleaning and disinfecting solution

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based contact lens cleaning and disinfecting solution
Study: NCT03987126

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human Milk Oligosaccharides (HMO)
Description: Sachet containing 10 grams of HMO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachet manufactured to mimic 10g of HMO
Study: NCT05144308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Images of the operated eye (s)
Description: Through the operating microscope or a slit lamp, dilated pupil. Taken on the day of surgery (D0) and at 1 week, 1 month and 3 months post-op
Study: NCT06070584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aerobic exercises with electrical treadmill for 30 min and inspiratory muscle training for 10 minutes.,
Description: aerobic exercises with moderate intensity in the form of walking on electrical treadmill

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercises with electrical treadmill for 30 min and inspiratory muscle training for 10 minutes.,
Description: aerobic exercises with moderate intensity in the form of walking on electrical treadmill